

This is a repository copy of *The effect of community groups and mobile phone messages on the prevention and control of diabetes in rural Bangladesh: study protocol for a three-arm cluster randomised controlled trial*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/151314/>

Version: Published Version

Article:

Fottrell, Edward, Jennings, Hannah orcid.org/0000-0002-8580-0327, Kuddus, Abdul et al. (10 more authors) (2016) The effect of community groups and mobile phone messages on the prevention and control of diabetes in rural Bangladesh: study protocol for a three-arm cluster randomised controlled trial. *Trials*. p. 600. ISSN 1745-6215

<https://doi.org/10.1186/s13063-016-1738-x>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

Takedown


If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

STUDY PROTOCOL

Open Access



The effect of community groups and mobile phone messages on the prevention and control of diabetes in rural Bangladesh: study protocol for a three-arm cluster randomised controlled trial

Edward Fottrell^{1*} , Hannah Jennings¹, Abdul Kuddus², Naveed Ahmed², Joanna Morrison¹, Kohenour Akter², Sanjit Kumar Shaha², Badrun Nahar², Tasmin Nahar², Hassan Haghparast-Bidgoli¹, A. K. Azad Khan², Anthony Costello^{1,3} and Kishwar Azad²

Abstract

Background: Increasing rates of type 2 diabetes mellitus place a substantial burden on health care services, communities, families and individuals living with the disease or at risk of developing it. Estimates of the combined prevalence of intermediate hyperglycaemia and diabetes in Bangladesh vary, and can be as high as 30% of the adult population. Despite such high prevalence, awareness and control of diabetes and its risk factors are limited. Prevention and control of diabetes and its complications demand increased awareness and action of individuals and communities, with positive influences on behaviours and lifestyle choices. In this study, we will test the effect of two different interventions on diabetes occurrence and its risk factors in rural Bangladesh.

Methods/design: A three-arm cluster randomised controlled trial of mobile health (mHealth) and participatory community group interventions will be conducted in four rural upazillas in Faridpur District, Bangladesh. Ninety-six clusters (villages) will be randomised to receive either the mHealth intervention or the participatory community group intervention, or be assigned to the control arm. In the mHealth arm, enrolled individuals will receive twice-weekly voice messages sent to their mobile phone about prevention and control of diabetes. In the participatory community group arm, facilitators will initiate a series of monthly group meetings for men and women, progressing through a Participatory Learning and Action cycle whereby group members and communities identify, prioritise and tackle problems associated with diabetes and the risk of developing diabetes. Both interventions will run for 18 months. The primary outcomes of the combined prevalence of intermediate hyperglycaemia and diabetes and the cumulative 2-year incidence of diabetes among individuals identified as having intermediate hyperglycaemia at baseline will be evaluated through baseline and endline sample surveys of permanent residents aged 30 years or older in each of the study clusters. Data on blood glucose level, blood pressure, body mass index and hip-to-waist ratio will be gathered through physical measurements by trained fieldworkers. Demographic and socioeconomic data, as well as data on knowledge of diabetes, chronic disease risk factor prevalence and quality of life, will be gathered through interviews with sampled respondents.

(Continued on next page)

* Correspondence: e.fottrell@ucl.ac.uk

¹Institute for Global Health, University College London, London, UK
Full list of author information is available at the end of the article



(Continued from previous page)

Discussion: This study will increase our understanding of diabetes and other non-communicable disease burdens and risk factors in rural Bangladesh. By documenting and evaluating the delivery, impact and cost-effectiveness of participatory community groups and mobile phone voice messaging, study findings will provide evidence on how population-level strategies of community mobilisation and mHealth can be implemented to prevent and control noncommunicable diseases and risk factors in this population.

Trial registration: ISRCTN41083256. Registered on 30 Mar 2016 (Retrospectively Registered).

Trial acronym: D-Magic: Diabetes Mellitus – Action through Groups or mobile Information for better Control.

Keywords: Diabetes, Intermediate hyperglycaemia, mHealth, Community mobilisation, Cluster randomised trial, Non-communicable disease,

Background

The global health importance of diabetes mellitus

Globally, type 2 diabetes mellitus (T2DM) and its complications are a growing concern among communities, health service providers and policymakers. The global prevalence of T2DM was estimated to be approximately 9% among adults in 2015, with around 75% of people living with T2DM in low- and middle-income countries [1]. Increasing rates of T2DM place a substantial burden on overstretched health care services, communities, families and individuals living with the disease or at risk of developing it. T2DM can lead to premature death; greatly increases the risk of cardiovascular disease; and, if not managed properly, can lead to serious morbidities, including nerve and renal complications [2]. Underlying the increasing prevalence of T2DM are complex genetic, environmental and lifestyle factors, including dietary changes and increases in risk factors such as smoking and lack of exercise.

T2DM in Bangladesh

The Bangladesh Demographic and Health Survey (BDHS) of over 17,000 households across Bangladesh found that approximately 25% of people aged 35 years or older in rural areas had abnormal fasting glucose and approximately 11% were diabetic [3]. Analysing the data from the BDHS, Akter et al. [4] reported a higher prevalence of T2DM among older people but no significant differences between males and females. There was a significant difference between the poorest and richest households in diabetes prevalence (6.4% of the poorest households and 19.2% richest households); the difference was considerably lower for impaired fasting glucose levels (19.7% and 23.5%, respectively) [4]. Although the prevalence of diabetes was considerably higher in urban households (15.2%) than in rural households (8.3%), for impaired fasting glucose, the prevalence was slightly higher for rural households (23.5%) than for urban households (19%). Other studies have shown lower levels of dysglycaemia, with Bhowmik et al. [5, 6] reporting a combined 2009 prevalence of impaired fasting glucose and T2DM of around 12–13% among adults aged

20 years or older in the rural but urbanising Chandra District, close to Dhaka. Sayeed et al. [7] estimated the prevalence of impaired fasting glucose and T2DM to be approximately 17% in adults aged 20 years and older in rural Mymensingh District, although trend data suggest that the prevalence is now higher [5, 7, 8]. In a systematic review and meta-analysis of studies on cardiovascular diseases and T2DM in Bangladesh, Saquib et al. [9] estimated the prevalence of diabetes in the period 2006–2010 to be 9%, though their data suggest a lower prevalence for rural areas, and the overall prevalence described between 1995 and 2010 ranged from 2% to more than 21%, with a pooled prevalence of 6.7% [9]. The prevalence of impaired fasting glucose and impaired glucose tolerance were estimated to be 7% and 8.2%, respectively, when data from all studies were pooled. More recently, Islam et al. [10] estimated the prevalence of T2DM in rural Narail District to be 7.2% and impaired fasting glucose to be 5.3%. The scant representative epidemiological data and conflicting estimates of disease prevalence highlight a need for large-scale, community-based surveys in rural Bangladesh, where, at present, prevalence estimates of intermediate hyperglycaemia and T2DM range between 12% and 30%, with apparent regional differences.

Few studies have described the incidence of diabetes in South Asia, although Asghar et al. [8] estimated the incidence among adults older than 20 years of age in rural Bangladesh between 1999 and 2004 to be 16.4 per 1000 person-years, increasing to 49 per 1000 person-years when adjusted for the age and sex distributions of their sample. Their data show that the incidence among individuals with impaired fasting glucose is approximately four times higher than among the total population; thus, the incidence of T2DM among these individuals can be estimated to be as high as 20% per year.

Despite the high levels of T2DM and intermediate hyperglycaemia, awareness and control of the condition are limited. The BDHS survey found that 59% and 65% of affected women and men, respectively, were not aware of their elevated blood glucose levels and that only 37% of diabetic women and 31% of diabetic men were

taking medication for their diabetes, with only 15% of women and 10% of men adequately controlling their blood glucose levels [3]. Reasons for low levels of awareness of one's diabetic status and control of it include inadequate health services for diagnosing and treating diabetes effectively, not being able to afford regular health care and treatment, and communicable diseases remaining a priority for Bangladeshi health programmes [11]. Additionally, those who are less educated and of lower socio-economic status are significantly less likely to have their T2DM diagnosed and treated [11]. A study by Islam et al. [10] on knowledge of T2DM and glycaemic control among patients with T2DM in Dhaka found that 45.6% of patients in the study had good knowledge of diabetes, 37.7% had moderate knowledge of it and 16.7% had poor knowledge. Whereas the majority of respondents in the study identified changing lifestyle and diet as important to managing diabetes, specifics such as excessive sugar intake were not recognised as a risk factor, and the importance of exercise was identified as important by only 24.3% of respondents. In a separate study in rural Bangladesh, knowledge that diabetes can cause eye disease and can be controlled by regular exercise was found to be higher among men than among women [12]. Knowledge of diabetes prevention, control, consequences and risk factors has been found to be significantly associated with higher education, higher monthly income, family history of diabetes and a longer duration of a diagnosis of T2DM [10, 12].

The need for further research and interventions

Research is needed to accurately describe the prevalence and patterns of T2DM, intermediate hyperglycaemia and risk factors for developing T2DM in rural Bangladesh. Although evidence demonstrates that lifestyle and other non-pharmacological interventions can prevent and delay the onset of T2DM [13], there is a lack of cost effective programs designed specifically for Bangladeshi populations, mindful of their own needs and resources.

Mobile health

One such approach is mobile health (mHealth), broadly defined as the application of mobile technology to improve health and strengthen health systems. There is evidence that mHealth techniques can increase adherence to medication in those already diagnosed with a chronic disease [14]. There is also some evidence of mHealth influencing behaviour change. Authors of a review of 14 intervention studies (in the United States, Europe, Australasia and South Korea) specifically on phone messages used to decrease obesity found that 11 of the studies using short message service (SMS) messages had a statistically significant effect on weight loss, diet or exercise, though the interventions did differ substantially and

questions remain about long-term impact [15]. Authors of a review of over 100 studies done over the last 25 years on chronic disease management and mHealth found that mobile messaging could assist with medicine adherence, although the results for chronic disease management were mixed, and more research into understanding and improving mHealth tools is needed [14].

Evidence of the effectiveness of mHealth interventions in low- and middle-income settings is mixed, with many lacking thorough evaluations [16, 17]. Of the mHealth interventions targeting T2DM in South Asia, a pilot study with patients with T2DM who received 1 year of SMS messaging regarding their treatment did reduce glycaemic levels as compared with the control group in India [18]. Ramachandran et al. [19] showed that the receipt of two to four mobile phone text messages per week with dietary and physical activity recommendations reduced the 2-year cumulative incidence of T2DM among professional men aged 35–55 years with impaired glucose tolerance by more than one-third in an individual randomised trial in southeastern India. Thus, although there is some evidence for mHealth having an impact on behaviour change and diabetic outcomes in a high-risk population, the effect at scale and in a general, rural population are unknown.

Community mobilisation

There is good evidence for lifestyle interventions preventing and/or delaying the onset of T2DM [13, 20], and involving the community and peer support is a cost-effective means of promoting lifestyle changes. Community-based peer support as a method of T2DM control intervention is starting to be tested in low-income countries [20–24], and encouraging evidence is emerging. However, relatively small sample sizes, short intervention durations, focus on high-risk individuals and the lack of a counterfactual limits interpretation of cause and effect as well as potential impact at a general population level.

A randomised control trial is currently being conducted in Kerala, India [20]. Through group motivation sessions, diabetes prevention education sessions, handbook and participant workbooks, its aims are to decrease T2DM and to improve behavioural, psychosocial, clinical and biomedical measures in the community. The results of the 2-year intervention study are not yet available.

Community mobilisation through Participatory Learning and Action (PLA) is a specific approach to community interventions that fosters community engagement in the identification of problems and threats to their health, the design and implementation of solutions to tackle these problems, and reflecting on their success. This approach has been shown to substantially improve maternal and newborn health [25]. However, the PLA

approach has not been tested on health issues beyond pregnancy, childbirth, neonatal [26, 27] and child health [28], and women's and reproductive health [29].

Methods/design

Goals

The goals of the present study are to prevent intermediate hyperglycaemia¹ and T2DM and to improve control of T2DM in Bangladesh.

Objectives

The objectives of the present study are to design and implement community mobilisation and mHealth interventions for the prevention and control of diabetes in rural Bangladesh and to test their effect on intermediate

hyperglycaemia and T2DM disease occurrence, management and risk factors in the population.

Research questions and outcomes

Table 1 details all study research questions, outcome measures and definitions.

Primary research questions

The following are the primary research questions of the study:

1. What is the effect of a participatory community mobilisation intervention on a) the prevalence of intermediate hyperglycaemia and T2DM and b) two year cumulative incidence of T2DM among

Table 1 Study outcomes and definitions

Outcome type	Outcome	Definition
Primary	The prevalence of intermediate hyperglycaemia and T2DM	Proportion of adults aged 30 years or older with WHO categorisations for intermediate hyperglycaemia (impaired fasting glucose or impaired glucose tolerance) and T2DM
	Two-year cumulative incidence of T2DM among individuals with intermediate hyperglycaemia at baseline	Proportion of adults aged 30 years or older with plasma glucose cut-off categorisations for intermediate hyperglycaemia at baseline who are categorised as T2DM at endline
Secondary	Blood pressure	Mean population diastolic and systolic blood pressure
	Prevalence of hypertension	Proportion of adults aged 30 years or older with systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg or self-reported current treatment with anti-hypertensive medication
	Body mass index	Mean population BMI
	Prevalence of overweight and obesity	Proportion of adults aged 30 years or older with a BMI of 23 kg/m ² or more
	Abdominal obesity	Proportion of adult men and women aged 30 years or older with waist-to-hip circumference ratio >0.9 or >0.85 , respectively
Explanatory	Quality of life score	Mean health-related quality of life (EQ-5D)
	Psychological distress among self-reported diabetics	Mean SRQ score among adults aged 30 years and older with self-reported diabetes
	Physical activity	Proportion of adults aged 30 years and older engaged in 30 minutes or more of physical activity per day on at least 5 days per week
Explanatory	Intake of fruit and/or vegetables	Mean number of portions of fruit or vegetables consumed per adult aged 30 years or older per day
	Population knowledge about diabetes risk factors, symptoms and complications	Proportion of adults aged 30 years and above who are (a) able to name at least one cause of diabetes, (b) able to report at least one symptom of diabetes, (c) able to report at least one complication of diabetes, (d) able to recognise complications of diabetes when prompted, (e) able to report at least one way to reduce the risk of getting diabetes and (f) able to report at least one way to control diabetes if diagnosed
	Self-awareness of diabetic status	Proportion of diabetics who correctly report their diabetic status
Explanatory	Receipt of treatment or advice for diabetes	Proportion of diabetics receiving care or advice from a medical professional

Abbreviations: BMI Body mass index, SRQ Self-Reporting Questionnaire, T2DM Type 2 diabetes mellitus, WHO World Health Organisation

individuals with intermediate hyperglycaemia at baseline?

2. What is the effect of an mHealth health promotion and awareness intervention on a) the prevalence of intermediate hyperglycaemia and T2DM and b) two year cumulative incidence of T2DM among individuals with intermediate hyperglycaemia at baseline?

Ancillary questions

The following are ancillary questions of the study:

What is the effect of a) a participatory community mobilisation intervention and b) an mHealth health promotion and awareness intervention on population:

- a. Blood pressure
- b. Prevalence of hypertension
- c. Body mass index
- d. Prevalence of overweight and obesity
- e. Prevalence of abdominal obesity
- f. Health-related quality of life
- g. Psychological distress among self-reported diabetics

Explanatory outcomes

In addition to the questions above, which will be answered in terms of primary and secondary outcomes (Table 1), five additional explanatory outcomes will be measured to better understand intervention processes and mechanisms of action in terms of changes in the following:

1. Population physical activity levels
2. Population intake of fruit and vegetables
3. Population knowledge about diabetes risk factors, symptoms and complications
4. Self-awareness of diabetic status
5. Proportion of diabetics receiving treatment or advice for diabetes

Trial design overview

The mHealth and community mobilisation interventions will be evaluated using a three-arm cluster randomised controlled trial design. The rationale is that each intervention is applied to the entire community and is not based on individual enrolment. Ninety-six villages will be randomised to either the mHealth intervention, community mobilisation or the control arm, and, given the nature of the interventions, allocation is not masked. Baseline and endline sample surveys measuring the prevalence of intermediate hyperglycaemia, diabetes, hypertension and various chronic disease risk factors, quality of life, as well as knowledge and care-seeking practices will be conducted before and after intervention delivery, respectively. Individuals identified at

baseline as having intermediate hyperglycaemia will be followed after the interventions to determine the incidence of T2DM among this high-risk population.

Setting

Faridpur District has a population of over 1.7 million people in an area of just over 2000 km² and is situated on the banks of the Padma River (Fig. 1). The district has a mainly agricultural economy, with the main crops being jute and rice. Large rivers throughout the district are prone to flooding, which can hinder travel and health care access in the area. The population is mainly Bengali, as is the case in most of Bangladesh, and almost 90% of the population of Faridpur are Muslim, with the remaining population largely Hindu. Administratively, Faridpur District is divided into nine upazillas, which in turn are divided into unions of approximately 25,000 population per union. The number of unions per upazilla in Faridpur District varies from 4 to 17. Each union is comprised of a number of mauzas, traditional administrative units that can be conceptualised as a village or collection of villages. Four upazillas in Faridpur District have been purposefully selected on the basis of being accessible to the district headquarters of the Diabetic Association of Bangladesh (BADAS) in Faridpur Sadar: These are Boalmari, Saltha, Madhukhali and Nagar-kanda. For each of these upazillas, the 2011 Bangladesh Census [30] was used to identify all mauzas with at least one village of between 750 and 2500 population size, 96 of which were selected for inclusion in the study.

In Bangladesh, primary care is provided by the government at union health and family welfare centres and at community clinics. In- and outpatient services are provided at subdistrict (upazilla) health complexes and hospitals, and tertiary care is provided at district hospitals and medical college hospitals. Inadequate facilities and trained health care providers, short supplies of medicines, and low responsiveness of services are challenges faced by the health care system in Faridpur District. Private health care provision is also available in Faridpur, including at the Diabetic Association Medical College Hospital in Faridpur Sadar.

The trial is implemented by the BADAS Perinatal Care Project (PCP), a non-profit, voluntary socio-medical organisation registered with the Ministry of Social Welfare that works closely with the Government of Bangladesh in collaboration with the Institute for Global Health, University College London.

Study population

In intervention areas, the target group for the mHealth and community mobilisation interventions are male and female permanent residents aged 30 years or older because this is the group that we expect to benefit the most from the community-level interventions. Note,




Fig. 1 Map of Faridpur District divided into nine upazillas (source: Local Government Engineering Department, Bangladesh)

however, that both interventions will be available and accessible to any community member, including health care providers. People are considered permanent residents of a village if the house that they normally live in is in that village. Temporary residents whose permanent home is in a village not included in the study or included in a different arm are not considered part of the intervention target population.

Interventions
mHealth

The mHealth intervention will consist of twice-weekly health behaviour-related and awareness-raising voice messages sent to individuals' mobile phones over a period of 18 months. Message content will be based on findings from formative research in the study area, application of behaviour change theories, review by medical experts and project staff, and specification of a creative brief which will be used by scriptwriters to create messages in a range of formats, such as mini-dramas, dialogues and songs. These will be performed by actors and recorded, and a signature jingle will be added to make the messages recognisable as coming from BADAS-PCP.

Each message will be recorded in Bangla in Dhaka, and recipients will receive distinct messages on two different occasions each week during the 18-month intervention period. Messages will be sent to all subscribed mobile phones using a service provided by MWorld (Dhaka, Bangladesh), a commercial third party.

The intervention will be available to all individuals with access to a mobile phone in the study areas. Individuals will need to register for the messaging service by providing their mobile phone number to community recruiters. Recruiters will coordinate community engagement activities, which will include community meetings, and mass communication methods, such as posters, leaflets, loudspeaker broadcasting and presentations at public service points (e.g., markets, clinics, places of worship). In addition to these recruitment drives, individuals will be able to self-enrol at any time throughout the study period.

A behaviour change theory-based approach to the mHealth intervention is likely to increase its chances of working [19, 31]. As such, the intervention will be developed using the capability, opportunity, motivation and behaviour (COM-B) theory for understanding behaviour

[32] and the Theoretical Domains Framework (TDF) to encourage change [33, 34].

The COM-B framework focuses on the interaction between capability, opportunity and motivation to generate behaviour. *Capability* is defined as an individual's psychological and physical capacity to engage in the activity concerned. It includes having the necessary knowledge and skills. *Motivation* is defined as all the brain processes that energise and direct behaviour, not just goals and conscious decision-making. It includes habitual processes, emotional responding and analytical decision-making. *Opportunity* is defined as all the factors that lie outside the individual that make the behaviour possible or prompt it. The different elements are inter-related. For example, opportunity can influence motivation, as can capability; engaging in a behaviour can alter capability, motivation and opportunity. The TDF framework (which corresponds with COM-B) was developed through consensus by behaviour change specialists and has been validated and refined [33, 35]. The framework simplifies and integrates existing behaviour change theories to make them accessible. It identifies 14 overarching behavioural domains that can be mapped according to capability, opportunity and motivation [35]. By categorising behaviour, different behaviour change techniques can be drawn on in order to encourage behaviour change [36]. Behavioural domains in the formative research that correspond with specific barriers to and enablers of behaviour change (e.g., knowledge, environmental context, beliefs about consequences) will be identified. In order to systematically address enablers and barriers, behaviour change techniques, such as shaping knowledge, modelling behaviour, and information about consequences, will be applied to the messages. Application of COM-B and the TDF to formative research and engagement with community members will involve an element of 'behavioural diagnosis' whereby it will be possible to identify areas of leverage for behaviour change within our target population.

Whilst the precise details of the mHealth intervention will emerge from the formative work, some general principles and descriptors of the intervention using the World Health Organisation (WHO) mHealth Technical and Evidence Review Group standard taxonomy of mHealth activities can be specified [37]. The target will be health promotion and disease prevention for the avoidance and continuous control of non-communicable disease risk factors, particularly those associated with T2DM, among the adult population using mobile phone voice messages as a communication channel.

Community mobilisation

The community mobilisation intervention will be an adaptation of a participatory women's group intervention implemented and evaluated in several settings and shown to

be effective at reducing neonatal mortality [27, 25]. The intervention will entail the initiation and facilitation of separate male and female participatory groups comprising approximately 20 members each. Groups will be open to all community members of any age; however, people with T2DM and high-risk individuals will be particularly encouraged to attend. Separate groups will be established for men and women because this is the approach most likely to achieve true participation within the rural Bangladeshi context, and there will be an equal number of male and female groups within each community mobilisation intervention cluster, with a minimum of one male and one female group per cluster. Joint meetings of men's and women's groups, as well as the wider community, will be encouraged. Enough groups will be established to ensure population coverage of approximately 1 group per 600 population or 1 group per 200 adults; however, the requirement of at least one male and one female group per cluster may increase population coverage beyond this target.

The groups will proceed through a series of 18 monthly meetings and several wider community-level meetings following the four phases of PLA (Fig. 2). Phase 1 will be focused on problem identification, whereby participants themselves identify and prioritise factors that affect their health, specifically threats that increase their risk of developing or failing to manage diabetes. Phase 2 involves the collective design of strategies that participants and their communities can implement to address the problems and threats identified in phase 1. During phase 3, the participants and community implement these strategies. In phase 4, the participants reflect on and evaluate the success of the strategies they have implemented. Problems that might be identified in phase 1 may include lack of awareness of signs and symptoms of diabetes, limited opportunity for physical exercise in a culturally appropriate or secure environment, or lack of choice in locally available food types. The community-led strategies that might be implemented may include large community meetings to raise awareness, community-led exercise groups, or cookery workshops highlighting healthier food types and cooking methods. Each meeting will comprise a range of activities using picture card games, discussion, role-playing, and storytelling to raise awareness and improve support, treatment and preventive behaviours for the population as a whole and for individuals with T2DM and their families. Those who attend groups will be encouraged to share their learning and key messages with other members of the community who were unable to attend, such as through household visits and establishing links with other groups in the area.

Participatory groups will be led by salaried group facilitators, each required to coordinate and facilitate several



Fig. 2 Four-phase participatory learning and action cycle underpinning the community mobilisation intervention

participatory group meetings per month. All facilitators will have a minimum of higher secondary school education, will be recruited from the study areas, and will receive 1 week's training on group facilitation and basic health messages related to chronic disease prevention and control, with a particular focus on T2DM. The facilitators will also be provided with a community facilitation manual with essential information on T2DM as well as its causes and control. The community facilitation manual will be developed during the formative phase of the project and will be aligned with national and international standards and based on materials developed by BADAS. Facilitators will be equipped with simple picture cards and flip charts graphically conveying health messages to stimulate discussion and critical thinking. Male groups will be led by a male facilitator and female groups will be led by a female facilitator. Facilitators will be motivated and provided with information and support through mobile phone messages and by support visits by two female participatory group coordinators based in Faridpur and a community group manager based in Dhaka.

Health system strengthening


All study clusters (intervention and control) will receive health system-strengthening activities. The reason to include a health system-strengthening component in our study is twofold. First, there is the ethical imperative to

ensure that the control areas also benefit from the study. Second, we expect some degree of a functioning 'supply side' local health system to be necessary for the success of the 'demand side' mHealth and community mobilisation interventions. Specific health system-strengthening initiatives will be tailored according to the situation analysis conducted during the formative phase of the project but are likely to include the training/refresher training of formal and informal health care workers in the prevention, diagnosis and treatment of T2DM, and the development of essential equipment inventories.

Randomisation

Using available maps, 24 mauzas from each of the 4 upazillas were purposefully selected on the basis of appearing to avoid contiguity between mauzas. A single eligible village within the selected mauza was designated the study cluster. In this way, it was intended that all study villages (clusters) would be separated from one another by a buffer zone of mauzas and villages not included in the study.

By stratified randomisation, the 96 villages will be randomly allocated to either the mHealth intervention arm, the community mobilisation arm or the control arm (32 in each), with each upazilla constituting 1 stratum (Fig. 3). The name of each village will be written on pieces of paper, colour-coded by upazilla, which, when folded, will be indistinguishable from each other. For



each upazilla, the 24 folded pieces of paper will be placed into a bottle and then drawn by community leaders and representatives at a public community orientation meeting in Faridpur attended by the project director, project manager and independent observers. The first eight villages drawn from the bottle will be allocated to 'arm A', the next eight villages to 'arm B' and the final eight villages to 'arm C'. After all 96 villages have been allocated to an arm, each of the 3 arms will be randomly assigned to either the mHealth intervention, community group intervention or control group by simultaneously drawing arm letter and intervention allocation from 2 separate bottles. The entire randomisation process will be filmed, and photographs will be taken to document every stage.

Minimising contamination

Every effort was made using available maps and population data to purposefully select study villages (clusters) to be non-contiguous to minimise contamination between intervention clusters and between intervention and control clusters. Further, exclusion of temporary or migratory individuals from the study surveys will minimise contamination between clusters.

Sample size

Sample size was determined using equations of Hayes and Bennett [38] and Hayes and Moulton [39]. The trial, with 3 treatment arms, will include 32 mHealth intervention clusters, 32 community mobilisation intervention clusters and 32 control clusters, with an average population of 487 adults aged 30 years or older per cluster. As detailed in the Background section above, estimates of intermediate hyperglycaemia and T2DM prevalence in Bangladesh vary [3–8]; therefore, our sample size calculation assumes a mid-range baseline/control prevalence of 17%. In the absence of published values, using an estimated, moderate between-cluster coefficient of variation (k) of 0.265, a

sample of 130 adults aged over 30 years per cluster will give 80% power at 95% confidence to detect a minimum of 21.5% reduction in disease prevalence in intervention clusters relative to control clusters.

Assuming a baseline prevalence of abnormal fasting glucose of 11%, the baseline surveys of 130 adults per cluster will identify approximately 15 individuals with intermediate hyperglycaemia per cluster. With an assumed 25% two-year cumulative incidence of T2DM among these high-risk individuals, two-year follow-up will give our study 78% power at 5% significance to detect a one-third (33%) reduction in cumulative incidence in intervention clusters relative to control clusters using a between-cluster coefficient of variation of 0.265. An additional 10% will be added to the sample list to allow for refusals, inability to contact and loss to follow-up, bringing the total target sample size to 143 per cluster, or 13,728.

Impact evaluation

Our trial has two primary outcomes. First is the combined prevalence of intermediate hyperglycaemia (i.e., impaired fasting glucose or impaired glucose tolerance) and T2DM among adults aged 30 years or older. We will use WHO and International Diabetes Federation definitions and blood glucose cut-offs for normoglycaemia, impaired fasting glucose, impaired glucose tolerance and T2DM, as summarised in Table 2 [40]. These levels have been used in previous studies in Bangladesh and in other Asian countries [3, 4].

Our second primary outcome is the cumulative 2-year incidence of T2DM among individuals identified with intermediate hyperglycaemia during our baseline survey.

Data collection and management

Sampling frame and sample

A sampling frame will be developed specifically for this study by listing all households and their eligible

Table 2 Glycaemia definitions and diagnostic criteria to be used in the D-Magic trial

Definition		Diagnostic criteria
Normoglycaemia		Fasting plasma glucose <6.1 mmol/L
Intermediate hyperglycaemia (sometimes termed <i>pre-diabetes</i>)	Impaired fasting glucose	Fasting plasma glucose ≥ 6.1 mmol/L to <7.0 mmol/L <i>and</i> Two-hour post-ingestion of 75-g glucose load plasma glucose <7.8 mmol/L
	Impaired glucose tolerance	Fasting plasma glucose <7.0 mmol/L <i>and</i> Two-hour post-ingestion of 75-g glucose load plasma glucose ≥ 7.8 mmol/L to <11.1 mmol/L
Type 2 diabetes mellitus		Fasting plasma glucose ≥ 7.0 mmol/L <i>or</i> ^a Two-hour post-ingestion of 75-g glucose load plasma glucose ≥ 11.1 mmol/L

Adapted from [40]

^aDiabetes cannot be excluded without 2-h post-oral glucose load test

members (non-pregnant permanent residents aged 30 years or older) within each of the study clusters. A sample of 143 adults aged 30 years or older will be randomly selected from this sampling frame from each study cluster using multi-stage simple random sampling. In the first stage, 143 households with at least 1 eligible adult resident will be selected using probability proportional to size sampling. At the next stage, a single eligible adult will be selected for inclusion in the survey using simple random sampling.

Surveys

Sampled individuals will be visited in their household and informed of the study, and their verbal consent will be obtained. Sampled individuals and data collectors are unlikely to be aware of their village's allocation to the intervention or control arm at the time of the baseline survey, but they are likely to be aware of allocation at the endline survey owing to the unblended nature of allocation. All sampled individuals in a single cluster will be informed of the anthropometric, blood glucose and blood pressure measurement requirements of the study and will be requested to attend a local centre on the morning of a specified day following an overnight fast. The centre will be established by the field team for the purposes of the study and will be at a central, convenient location in the village. Collection of questionnaire data will take place at the respondents' homes before or after the physical measurements or at the time of physical measurement in the testing centre.

Following extensive training and field practice, pairs of trained fieldworkers (one male and one female) with at least higher secondary school qualifications will be

trained to measure blood pressure, blood glucose concentration, body weight, height, and waist and hip girth using standard methods. Blood pressure will be measured using the OMRON HBP 1100 Professional Blood Pressure Monitor (OMRON Healthcare, Kyoto, Japan). Two sitting measurements will be taken at approximately 5-minute intervals, and the respondent's blood pressure will be obtained by averaging these measurements. Measurements of height, weight, and waist and hip girth will be taken with subjects wearing light clothes and without shoes. The weighing tools will be calibrated daily by known weight. For height, the subject will stand in erect posture vertically touching the occiput, back, hip and heels to the wall while gazing horizontally in front and keeping the tragus and lateral orbital margin in the same horizontal plane. Waist girth will be measured by placing a non-stretchable plastic tape horizontally midway between the 12th rib and the iliac crest on the mid-axillary line. Similarly, hip circumference will be measured by taking the extreme end posteriorly and the symphysis pubis anteriorly. Physical measurements will be recorded on specifically designed forms and later entered into a mobile phone data entry system.

Blood glucose will be measured using the OneTouch Ultra glucometer (LifeScan, Inc., Milpitas, CA, USA) in whole blood obtained by finger prick from capillaries in the middle or ring finger after an overnight fast of 8–12 h, an approach that is widely used in resource-limited countries [4]. The OneTouch Ultra glucometer automatically converts whole-blood glucose readings to the equivalent plasma value, so no additional conversion will be required. All individuals will then receive a 75-g glucose load dissolved in 250 ml of water and will have a repeat capillary blood test within 5 minutes of 120 - minutes post-ingestion to determine glucose tolerance status and differentiate between individuals with intermediate hyperglycaemia and those with diabetes according to WHO criteria (Table 2).

Detailed information on the socio-demographic characteristics of all sampled individuals will be collected by the trained fieldworkers using a structured survey instrument adapted from the WHO STEPwise tool [41] and the 2011 Bangladesh Demographic and Health Survey [3]. The instrument will be designed to measure the background demographic and socio-economic characteristics, lifestyle and behavioural risk factors, diabetes awareness indicators, health-seeking behaviour, and costs of care-seeking among study participants. The EQ-5D questionnaire will be used to measure quality of life [42]. Questionnaire data will be gathered using Samsung Galaxy Grand Prime (Samsung, Seoul, South Korea) large-screen smartphones (US\$200) using ODK Collect open-source software.

Fieldworker activity will be monitored by a team of supervisors with experience in field data collection and survey techniques. Supervisors will observe data collection processes and conduct some repeat measurements for verification in a random selection of cases. One supervisor will have the sole responsibility of collecting data from each individual fieldworker's mobile phone onto a laptop every 3 days (maximum) and transferring these data to the district project office for data-checking before final transfer of the data to Dhaka. Individuals unable to participate in the data collection at the testing centre or on the specified day will be followed and asked to participate in the study at a later date.

Implementation research and process evaluation

Detailed quantitative and qualitative process evaluation research will be done in intervention and control areas throughout the trial to consider the effect of context on interventions, to describe the implementation of the interventions, and to help explain any observed intervention effect or lack of effect. Process data will be used throughout implementation to inform intervention design and delivery and will help to develop theory about how the interventions impact health outcomes. This will enable assessment of the feasibility, acceptability, scalability and external validity (or replicability) of the interventions.

Analysis

Interim analysis and stopping rules

A meeting of an independent Data and Safety Monitoring Board (DSMB) will be convened according to the DAMOCLES charter after entry and cleaning of baseline survey data and approximately 9 months' worth of implementation and process data. The DSMB will be tasked with providing an independent, objective review of the study implementation and baseline data and advise on any extension or modification of the trial. In particular, it will review the following:

1. Process indicators, including community group coverage, mHealth coverage (subscription rates) and adherence to the implementation plan
2. The adequacy of the sample size and the validity of sample size calculation assumptions about baseline prevalence and incidence and intra-cluster correlation coefficients
3. The comparability of treatment arms according to baseline survey data
4. Data quality
5. Endline survey design
6. The proposed trial analysis plan, including methods for adjustment of stratification and clustering and intervention effect measures to be reported

Intervention allocation will be masked to the DSMB. There are no stopping rules, because we do not expect the intervention to have adverse effects at either the cluster or participant level.

Intention-to-treat analysis

The trial will test the effect of a community mobilisation intervention and an mHealth intervention, as described previously, relative to a control group. We do not intend to directly compare the effects of each intervention relative to the other. Analysis will be based on intention to treat at the individual and cluster levels as appropriate for the outcome measures. The intention-to-treat population includes only adults aged 30 years or older who are permanently residing in the village in which they are surveyed. Participants with missing data on the primary outcomes will be excluded from primary outcome analysis but may be included in secondary outcome analysis, depending on data completeness. All analyses will be carried out with adjustment for the stratified, clustered study design, without and with adjustment for potential confounders resulting from imbalance between study clusters, which will be selected on the basis of their importance as a determinant of the outcomes rather than the size or significance of any difference between arms. Estimates of the intervention effects will be presented with 95% confidence intervals. No correction for multiplicity will be made. Analysis will be conducted using STATA statistical software (StataCorp, College Station, TX, USA).

Economic evaluation and equity impact analysis

Cost and cost-effectiveness analyses will take a societal perspective, assessing the economic impact for all parties affected by the interventions, including implementing agencies (project or program costs), health care providers (at local and national levels), and users or households. Program costs will be collected prospectively from the project accounts, and data on provider costs will be collected retrospectively from a random sample of primary care providers in the project area. Costs incurred by users or households will be collected during household and other follow-up surveys. All costs will be estimated from both a financial and an economic perspective, adjusted for inflation using the Bangladesh Consumer Price Index (CPI) and presented in international dollars. Incremental cost-effectiveness ratios will be evaluated in terms of the cost per case of intermediate hyperglycaemia and T2DM prevented, cost per case of diabetes prevented among individuals with intermediate hyperglycaemia at baseline, cost per millimetre of mercury reduction in systolic blood pressure, and other secondary outcomes to be detailed in a separate economic evaluation protocol to be submitted for

publication. The robustness of the cost-effectiveness results will be assessed through a series of sensitivity analyses. In addition to cost-effectiveness analysis, an equity-impact analysis will be conducted to assess whether the interventions have improved the equity of health service delivery and are improving the health status of those most in need.

Timetable

The intervention period is between June 2016 and December 2017. A time schedule for project activities is displayed in Fig. 4.

Ethics

Approvals

The trial has been reviewed and approved by the University College London Research Ethics Committee (4766/002) and by the BADAS Ethical Review Committee (BADAS-ERC/EC/t5100246). The trial has been registered and assigned an International Standard Randomised Controlled Trial number (ISRCTN41083256).

Community consultation

Community leaders will be identified and approached to obtain permission to deliver the interventions and conduct the evaluation surveys. Orientation meetings will be held to explain the project aims, and community leaders will be invited to observe the randomisation process. The concept of random sampling for inclusion in the study surveys will be explained. Further,

community advisory committees composed of community representatives and leaders will be established in each study upazilla with the purpose of advising and informing the research process and linking the research team to the community [43, 44].

Consent

Individual participation in the community meetings and receipt of the mHealth messages will be on a voluntary basis, and participants can choose to withdraw from either intervention at any time. Prior to all interviews and focus group discussions, the purpose of the data collection will be explained, an information sheet will be provided, and consent from the interviewee will be obtained. Respondents will be told that they can decline to participate in the study and can refuse to answer any question. Access to the identifiable individual-level data will be restricted to surveillance and data entry staff as well as analysts from the study team.

Treatment of illness in study areas

Fieldworkers will be trained to refer any individuals identified with possible intermediate hyperglycaemia, diabetes or hypertension to an appropriate health care facility for consultation and confirmatory testing.

Benefits to control areas

We have equipoise on the interventions under test: the effect of an mHealth messaging intervention or participatory groups on T2DM and its risk factors is unknown

TIMEPOINT	STUDY PERIOD									
	Enrolment	Allocation	Post-allocation							Close-out
	Jul/Aug 2015	Sept 2015	Oct-Dec 2015	Jan-Mar 2016	Apr-Jun 2016	Jul-Sep 2016	Oct-Dec 2016	Jan-Dec 2017	Jan-Mar 2018	Apr-Jun 2018
ENROLMENT:										
Identification of suitable clusters										
Community-level (cluster) orientation and informed consent										
Formative research & intervention development										
Allocation										
INTERVENTIONS:										
mHealth (32 clusters)										
PLA Community Mobilisation (32 clusters)										
Health Systems Strengthening Activities (96 clusters)										
ASSESSMENTS:										
Sampling frame development										
Baseline survey enrolment, consent & data collection										
Endline survey enrolment, consent & data collection										
Process Evaluation										
DSMB										
Analysis, reporting & dissemination										

Fig. 4 Study time frame. *DSMB* Data and Safety Monitoring Board, *PLA* Participatory Learning and Action

in the Bangladeshi context. It is therefore important to test the effect of this intervention using a randomised trial design. It is ethically important that the control areas also benefit from the study. They will do so in two ways. First, they will benefit directly through the health system-strengthening activities that will be undertaken in both study arms. Second, they will benefit indirectly through the strengthening of the evidence base on the burden of T2DM and its risk factors and our advocacy activities at the local, national and international levels.

Scalability

The potential for scaling up the interventions under investigation in Bangladesh is high. Scale-up would be facilitated by the fact that the project partner (BADAS) is the largest health care provider in Bangladesh after the government and has strong links with government agencies as well as private sector agents relevant to scale-up, such as mobile telecommunications companies.

Role of funder

Peer review of the grant application influenced the design of the study and study outcomes. Beyond that, the funder will have no role in the design of the study; the data collection, analysis and interpretation; or the write-up of the findings.

Dissemination

Successful completion of the Bangladesh D-Magic trial will contribute to the science of the evaluation of complex community-based interventions, behaviour change and implementation research. Beyond these academic endeavours, we anticipate that our study activities will benefit individuals and communities in our study areas, service providers and policymakers in Bangladesh, and advocacy and implementation groups tackling diabetes in Bangladesh and internationally. Specifically, the data generated from the epidemiological description of the burden of diabetes and its risk factors in Bangladesh, as well as the anthropological perspectives added through formative research, will deepen understanding of the issue within the study context. Impact and process evaluation of two discrete interventions will help to identify cost-effective ways to address the burden of diabetes and non-communicable disease risk factors in a low-income, rural South Asian setting. Study activities and findings will be disseminated to a range of audiences, including study participants, service providers and policymakers, through a range of appropriate means, including workshops, dissemination meetings and peer-reviewed publications.

Discussion

This protocol describes the Bangladesh D-Magic trial which, through implementation science methods,

mixed methods process evaluation and rigorous impact evaluation using a three arm cluster randomised controlled design, will increase our understanding of diabetes and other non-communicable disease burdens and risk factors in rural Bangladesh. Study findings will provide evidence on how population-level strategies of community mobilisation and mHealth can be implemented to prevent and control non-communicable diseases and risk factors in this population.

Trial status

The trial is ongoing.

Endnotes

¹We use the term *intermediate hyperglycaemia* to represent measures of glucose that are categorised as impaired fasting glucose or impaired glucose tolerance according to the WHO definitions outlined in Table 2.

Abbreviations

BADAS: Diabetic Association of Bangladesh; BDHS: Bangladesh Demographic and Health Survey; BMI: Body mass index; COM-B: Capability, opportunity, motivation and behaviour; CPI: Consumer Price Index; DSMB: Data and Safety Monitoring Board; mHealth: Mobile health; PCP: Perinatal Care Project; PLA: Participatory Learning and Action; SMS: Short message service; SRQ: Self-Regulation Questionnaire; T2DM: Type 2 diabetes mellitus; TDF: Theoretical Domains Framework; WHO: World Health Organisation

Acknowledgements

We thank our technical advisory committees in the United Kingdom (Graham Hitman, Katherine Fielding, Sophia Wilkinson, Lou Atkins, David Beran) and Bangladesh (Fida Mehran, Abu Sayeed, Farid Uddin, Tofail Ahmed, Bishwajit Bhowmik, Hajera Mahtab), as well as the independent technical experts who provided valuable comments on aspects of intervention design and impact evaluation.

Funding

The trial is funded by the Medical Research Council UK (MR/M016501/1) under the Global Alliance for Chronic Diseases (GACD) Diabetes Programme.

Availability of data and materials

Not applicable.

Authors' contributions

EF is scientific coordinator and principal investigator of the trial. He led the design of the study, wrote the first draft of the study protocol, and will participate in the analysis and interpretation of data. AK is project manager of the trial, overseeing all activities. JH is research associate of the study, contributing to design and interpretation of formative research and the development of interventions as well as review of the literature on mHealth and community interventions. JM is senior research associate of the project, leading design of formative research methods, intervention development and process evaluation. HHB is senior research associate of the project, leading the economic evaluation and equity components. NA contributed to protocol development, fieldworker training, and development of interventions. SKS coordinates survey data collection and processes and will participate in the analysis and interpretation of data. BN supports data collection and leads all data management processes. TN contributed to the design of interventions and is responsible for the implementation of the community groups. KAK contributed to the design, execution and interpretation of formative research and contributes to process evaluation. AKAK provided technical oversight on intervention development. AC contributed to the initial conception of the project and will participate in the interpretation of data. KAZ is project director, contributed to the design of the study, leads the implementation of the trial and will participate in interpretation of data. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The trial has been reviewed and approved by the University College London Research Ethics Committee (4766/002) and by the Ethical Review Committee of the Diabetic Association of Bangladesh (BADAS-ERC/EC/t5100246). The trial has been registered and assigned an International Standard Randomised Controlled Trial Number (ISRCTN41083256).

Consent

Community and individual participation in the study will be on a voluntary basis, and participants can choose to withdraw at any time. Prior to all interviews and focus group discussions, the purpose of the data collection will be explained, an information sheet provided, and consent from the interviewee obtained. Respondents will be told that they can decline to participate in the study and can refuse to answer any question. Access to the identifiable individual-level data will be restricted to surveillance and data entry staff as well as analysts from the study team.

Author details

¹Institute for Global Health, University College London, London, UK. ²Diabetic Association of Bangladesh, Dhaka, Bangladesh. ³World Health Organisation, Geneva, Switzerland.

Received: 23 May 2016 Accepted: 3 December 2016

Published online: 19 December 2016

References

- International Diabetes Federation (IDF). IDF diabetes atlas. 7th ed. Brussels: IDF; 2015.
- International Diabetes Federation (IDF). Global guideline for type 2 diabetes. Brussels: IDF; 2012.
- National Institute of Population Research and Training (NIPORT). Mitra and Associates, MEASURE DHS/ICF International. Bangladesh demographic and health survey 2011. Calverton: MEASURE DHS/ICF International; 2013.
- Akter S, Rahman MM, Abe SK, Sultana P. Prevalence of diabetes and prediabetes and their risk factors among Bangladeshi adults: a nationwide survey. *Bull World Health Organ*. 2014;92(3):204–13A.
- Bhowmik B, Afsana F, My Diep L, Binte Munir S, Wright E, Mahmood S, et al. Increasing prevalence of type 2 diabetes in a rural Bangladeshi population: a population based study for 10 years. *Diabetes Metab J*. 2013;37(1):46–53.
- Bhowmik B, Binte Munir S, Ara Hossain I, Siddiquee T, Diep LM, Mahmood S, et al. Prevalence of type 2 diabetes and impaired glucose regulation with associated cardiometabolic risk factors and depression in an urbanizing rural community in Bangladesh: a population-based cross-sectional study. *Diabetes Metab J*. 2012;36(6):422–32.
- Sayeed MA, Mahtab H, Akter Khanam P, Abdul Latif Z, Keramat Ali SM, et al. Diabetes and impaired fasting glycemia in a rural population of Bangladesh. *Diabetes Care*. 2003;26(4):1034–9.
- Asghar S, Khan AK, Ali SM, Sayeed MA, Bhowmik B, Diep ML, et al. Incidence of diabetes in Asian-Indian subjects: a five year follow-up study from Bangladesh. *Prim Care Diabetes*. 2011;5(2):117–24.
- Saquiub N, Saquiub J, Ahmed T, Khanam MA, Cullen MR. Cardiovascular diseases and type 2 diabetes in Bangladesh: a systematic review and meta-analysis of studies between 1995 and 2010. *BMC Public Health*. 2012;12:434.
- Islam FM, Chakrabarti R, Islam MT, Wahab M, Lamoureux E, Finger RP, et al. Prediabetes, diagnosed and undiagnosed diabetes, their risk factors and association with knowledge of diabetes in rural Bangladesh: the Bangladesh Population-based Diabetes and Eye Study. *J Diabetes*. 2016;8(2):260–8.
- Rahman MS, Akter S, Abe SK, Islam MR, Mondal MN, Rahman JA, et al. Awareness, treatment, and control of diabetes in Bangladesh: a nationwide population-based study. *PLoS One*. 2015;10(2):e0118365.
- Islam FM, Chakrabarti R, Dirani M, Islam MT, Ormsby G, Wahab M, et al. Knowledge, attitudes and practice of diabetes in rural Bangladesh: the Bangladesh Population based Diabetes and Eye Study (BPDES). *PLoS One*. 2014;9(10):e110368.
- Rawal LB, Tapp RJ, Williams ED, Chan C, Yasin S, Oldenburg B. Prevention of type 2 diabetes and its complications in developing countries: a review. *Int J Behav Med*. 2012;19(2):121–33.
- Hamine S, Gerth-Guyette E, Faulx D, Green BB, Ginsburg AS. Impact of mHealth chronic disease management on treatment adherence and patient outcomes: a systematic review. *J Med Internet Res*. 2015;17(2):e52.
- Shaw R, Bosworth H. Short message service (SMS) text messaging as an intervention medium for weight loss: a literature review. *Health Informatics J*. 2012;18(4):235–50.
- Gurman TA, Rubin SE, Roess AA. Effectiveness of mHealth behavior change communication interventions in developing countries: a systematic review of the literature. *J Health Commun*. 2012;17 Suppl 1:82–104.
- Hall CS, Fottrell E, Wilkinson S, Byass P. Assessing the impact of mHealth interventions in low- and middle-income countries – what has been shown to work? *Glob Health Action*. 2014;7:25606.
- Shetty AS, Chamukuttan S, Nanditha A, Raj RK, Ramachandran A. Reinforcement of adherence to prescription recommendations in Asian Indian diabetes patients using short message service (SMS) – a pilot study. *J Assoc Physicians India*. 2011;59:711–4.
- Ramachandran A, Snehalatha C, Ram J, Selvam S, Simon M, Nanditha A, et al. Effectiveness of mobile phone messaging in prevention of type 2 diabetes by lifestyle modification in men in India: a prospective, parallel-group, randomised controlled trial. *Lancet Diabetes Endocrinol*. 2013;1(3):191–8.
- Sathish T, Williams ED, Pasricha N, Absetz P, Lorgelly P, Wolfe R, et al. Cluster randomised controlled trial of a peer-led lifestyle intervention program: study protocol for the Kerala diabetes prevention program. *BMC Public Health*. 2013;13:1035.
- Balagopal P, Kamalamma N, Patel TG, Misra R. A community-based diabetes prevention and management education program in a rural village in India. *Diabetes Care*. 2008;31(6):1097–104.
- Balagopal P, Kamalamma N, Patel TG, Misra R. A community-based participatory diabetes prevention and management intervention in rural India using community health workers. *Diabetes Educ*. 2012;38(6):822–34.
- Assah FK, Atanga EN, Enoru S, Sobngwi E, Mbanya JC. Community-based peer support significantly improves metabolic control in people with type 2 diabetes in Yaounde, Cameroon. *Diabet Med*. 2015;32(7):886–9.
- Baumann LC, Frederick N, Betty N, Josephine E, Agatha N. A demonstration of peer support for Ugandan adults with type 2 diabetes. *Int J Behav Med*. 2015;22(3):374–83.
- Prost A, Colbourn T, Seward N, Azad K, Coomarasamy A, Copas A, et al. Women's groups practising participatory learning and action to improve maternal and newborn health in low-resource settings: a systematic review and meta-analysis. *Lancet*. 2013;381(9879):1736–46.
- Azad K, Barnett S, Banerjee B, Shaha S, Khan K, Rego AR, et al. Effect of scaling up women's groups on birth outcomes in three rural districts in Bangladesh: a cluster-randomised controlled trial. *Lancet*. 2010;375(9721):1193–202.
- Fottrell E, Azad K, Kuddus A, Younes L, Shaha S, Nahar T, et al. The effect of increased coverage of participatory women's groups on neonatal mortality in Bangladesh: a cluster randomized trial. *JAMA Pediatr*. 2013;167(9):816–25.
- Younes L, Houweling TAJ, Azad K, Kuddus A, Shaha S, Haq B, et al. The effect of participatory women's groups on infant feeding and child health knowledge, behaviour and outcomes in rural Bangladesh: a controlled before-and-after study. *J Epidemiol Community Health*. 2015;69:374–81.
- Harris-Fry HA, Azad K, Younes L, Kuddus A, Shaha S, Nahar T, et al. Formative evaluation of a participatory women's group intervention to improve reproductive and women's health outcomes in rural Bangladesh: a controlled before and after study. *J Epidemiol Community Health*. 2016;70(7):663–70.
- Bangladesh Bureau of Statistics. Bangladesh Population and Housing Census 2011. Dhaka: Bangladesh Bureau of Statistics; 2013.
- Cotter AP, Durant N, Agne AA, Cherrington AL. Internet interventions to support lifestyle modification for diabetes management: a systematic review of the evidence. *J Diabetes Complications*. 2014;28(2):243–51.
- Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. *Implement Sci*. 2011;6:42.
- Michie S, Johnston M, Abraham C, Lawton R, Parker D, Walker A. Making psychological theory useful for implementing evidence based practice: a consensus approach. *Qual Saf Health Care*. 2005;14(1):26–33.
- Michie S, Richardson M, Johnston M, Abraham C, Francis J, Hardeman W, et al. The behavior change technique taxonomy (v1) of 93 hierarchically

- clustered techniques: building an international consensus for the reporting of behavior change interventions. *Ann Behav Med.* 2013;46(1):81–95.
35. Cane J, O'Connor D, Michie S. Validation of the theoretical domains framework for use in behaviour change and implementation research. *Implement Sci.* 2012;7:37.
 36. French SD, Green SE, O'Connor DA, McKenzie JE, Francis JJ, Michie S, et al. Developing theory-informed behaviour change interventions to implement evidence into practice: a systematic approach using the Theoretical Domains Framework. *Implement Sci.* 2012;7:38.
 37. Agarwal S, LeFevre AE, Lee J, L'Engle K, Mehl G, Sinha C, et al. Guidelines for reporting of health interventions using mobile phones: mobile health (mHealth) Evidence Reporting and Assessment (mERA) Checklist. *BMJ.* 2016; 352:i1174.
 38. Hayes RJ, Bennett S. Simple sample size calculation for cluster-randomized trials. *Int J Epidemiol.* 1999;28(2):319–26.
 39. Hayes RJ, Moulton LH. Cluster randomised trials. Boca Raton: CRC Press; 2009.
 40. World Health Organisation (WHO), International Diabetes Federation (IDF). Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. Geneva: WHO; 2006.
 41. World Health Organisation (WHO). Surveillance of risk factors for noncommunicable disease: the WHO STEPwise approach. WHO document WHO/NMH/CCS/01.2002. Geneva: WHO; 2002.
 42. Saleh F, Ara F, Mumu SJ, Hafez MA. Assessment of health-related quality of life of Bangladeshi patients with type 2 diabetes using the EQ-5D: a cross-sectional study. *BMC Res Notes.* 2015;8:497.
 43. Shubis K, Juma O, Sharifu R, Burgess B, Abdulla S. Challenges of establishing a community advisory board (CAB) in a low-income, low-resource setting: experiences from Bagamoyo, Tanzania. *Health Res Policy Syst.* 2009;7:16.
 44. Pinto RM, Spector AY, Valera PA. Exploring group dynamics for integrating scientific and experiential knowledge in community advisory boards for HIV research. *AIDS Care.* 2011;23(8):1006–13.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

